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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Being a carrier of 
Alport mutations may 
not be so benign
Mutations of the COL4A5 gene, encod-
ing the a5-chain of type IV collagen, 
lead to X-linked Alport syndrome 
(XLAS) in males, and those in COL4A4/
COL4A3 to the autosomal recessive form 
(ARAS). The incidence of renal involve-
ment in female carriers of XLAS and in 
heterozygotes of ARAS with thin base-
ment membrane disease may not be as 
negligible as originally assumed. In this 
issue, a European consortium reports 
on the risk of renal involvement in het-
erozygous carriers of XLAS and ARAS 
and evaluates nephroprotective effects 
of renin–angiotensin–aldosterone sys-
tem (RAAS) blockade in these patients. 
Surprisingly, XLAS and ARAS carriers 
have similar and non-negligible inci-
dences of renal replacement therapy 
(11% and 15 %), proteinuria (35% and 
33%), and impaired creatinine clearance 
(17% and 15%). RAAS inhibition sig-
nificantly delayed the onset of end-stage 
renal failure in the heterozygote carriers. 
Thus, carriers of XLAS and ARAS with 
thin basement membrane disease should 
be followed carefully for renal involve-
ment, and therapy with RAAS inhibition 
should be started in a timely manner as 
it can markedly delay the onset of renal 
failure. See page 779.
Role of necroptosis in 
acute kidney injury
Until recently, programmed cell death 
was thought to occur almost exclusively 
via apoptosis, which is dependent on 
the activity of caspases. Necrosis was 
considered to be a disorderly manner of 
cell death, occurring in catastrophically 
injured cells and characterized by uncon-
trolled release of cellular contents, result-
ing in local tissue injury. Recent research 
has identified programmed necrosis, 
known as necroptosis, as a novel path-
way of non-caspase-mediated cell death. 
Linkermann et al. provide the first report 
of a role for necroptosis in mediating 
renal injury. They found that inhibiting 
necroptosis, but not apoptosis, protects 
mice from renal ischemia/reperfusion 
injury. Therefore, preventing necroptosis 
is a promising new strategy for preventing 
and/or treating renal injury. See page 751.
Effect of vessel 
configuration on AV 
fistula maturation
Though arteriovenous fistulae (AVFs) 
have superior long-term clinical out-
comes compared with other forms of 
vascular hemodialysis access, early AVF 
failure occurs in a significant proportion 
of patients. Krishnamoorthy et al. used 
a novel approach to study whether AVF 
geometry affects the rate of flow and 
maturation. They created femoral AVFs 
in pigs, with each pig having straight 
and curved AVFs on opposing sides, and 
measured changes in luminal diameter 
and flow. The authors report that curved 
AVFs had greater increases in flow and 
luminal diameter than straight AVFs 
after 4 weeks. This raises the possibility 
that successful AVF maturation could be 
promoted by as simple a modification of 
the surgical technique as changing from 
a straight to a curved AVF formation. 
See page 745.
